Investor Centre
Our broad clinical and preclinical pipeline in oncology and behavioural brain disorders focuses on indications including glioblastoma, neurodevelopmental disorders, addiction, anxiety, fatigue and narcolepsy.
0.22 GBX
Volume:
2,099,052
Market Capitalisation (m)
£4.81
Diversified portfolio in high demand therapeutic areas
Diversified portfolio in high demand therapeutic areas
- Focus on brain disorders
- Pre-clinical CNS pipeline in indications with high unmet need – addiction, anxiety, narcolepsy
- Clinical stage, grant funded collaboration with Erasmus Medical Centre for SFX-01 in glioblastoma.
Significant market potential
Significant market potential
- Near clinic-ready CNS assets offer opportunity to build substantial value quickly
- Addiction market alone currently worth $40bn worldwide
- Out-licensing transactions at early and mid-stage development in the £00million range
- Lack of suitable drug candidates currently in development for addictive behaviours
Compelling data
Compelling data
- Heavily de-risked lead CNS programme – an Ox-1 inhibitor – with short path to key inflection point of clinical readiness
- Ox-1 antagonist (blocker) exhibits best-in-class potential
- DAT inhibitor candidate molecule at late preclinical stage targeting fatigue and narcolepsy
- High quality clinical and pre-clinical data on all assets, validated by third party experts
- Published in peer reviewed journals
Lead programmes funded to key inflection points
Lead programmes funded to key inflection points
- Ox-1 programme funded to clinical trial- readiness – allowing us to unlock potential commercial opportunities
- SFX-01 programme with Erasmus Medical Centre funded by KWF Dutch Cancer Society
- Cash runway to end 2026 – amongst the longest cash runways of UK and European listed biotech companies
- Capital efficient, virtual company with low overheads
Experienced leadership team
Experienced leadership team
- Leadership team brings extensive experience from across R&D, business development, biotech company building and successful exits
- Collectively delivered numerous biotech licensing deals and developed drugs to market
- Track record of effective company financing via both capital markets and non-dilutive grant funding
TheraCryf plc Investor Presentation
09 - July - 2025
TheraCryf shares the corporate presentation following the AGM held on the 9th July 2025.
Major Shareholders
| Current Shareholder | Number of shares | Percentage holding |
|---|---|---|
| Northern Standard Limited | 422,727,272 | 19.67% |
| First Equity Limited | 179,000,000 | 8.33% |
| T and I Limited | 160,000,000 | 7.45% |
| Oberon Investments Limited | 80,475,000 | 3.74% |
| Spreadex Limited | 80,009,545 | 3.72% |
| A Leach | 80,000,000 | 3.72% |
| S Gibeon | 71,400,000 | 3.32% |
| J. R. Kight | 56,100,000 | 2.61% |
| Rathbones Investment Management Ltd | 24,835,704 | 1.16% |
| Octopus Investments | 21,875,000 | 1.02% |
| Vulpes Investment Management Pte Ltd | 20,554,191 | 0.96% |
| Seneca Partners Limited | 16,301,456 | 0.76% |
The number of ordinary shares in issue is 2,148,963,739. Directors hold 13,184,793 and 2,135,778,946 are in public hands. The Company does not hold any shares in the Treasury.
